| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8948211 | Journal of Proteomics | 2018 | 18 Pages |
Abstract
A better knowledge of histone and non-histone acetylated protein profile after HDAC inhibitors (HDACis) treatment can strongly support the understanding of non-clinical and clinical investigations in a pharmaceutical drug discovery program. Relative quantification using mass spectrometry -based proteomics after acetylated-lysine peptide enrichment and a targeted antibody-based immunoassay (DigiWest) are proposed as complementary technologies to assess the modifications of the acetylated proteome. Quisinostat (JNJ-26481585) a novel second-generation HDACi with highest potency for HDAC1 was better characterized in vitro in HuT78 cells to support and understand cutaneous T-cell lymphoma (CTCL) therapeutic research program.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Bruno Méhul, Agnes Perrin, Karine Grisendi, Antonio Núñez Galindo, Loïc Dayon, Corinne Ménigot, Yves Rival, Johannes J. Voegel,